Citations

Showing 10 of 108083 citations.

Clinical flow cytometry: it's not just about reaching a diagnosis
Craig, Fiona E.

Mayo Clinic

Cytometry Part B: Clinical Cytometry | August 18, 2017 | Volume: 92 | Issue: 5 | Pages: 329-330

10.1002/cyto.b.21585 | PMID 28834197 Get It

Papilloedema and Autoimmune Retinopathy from Systemic Lupus Erythematosus
Chen, John J. , Kumar, Neeraj , McEvoy, Kathleen M., Leavitt, Jacqueline A., Chen, John J

Mayo Clinic

Neuro-Ophthalmology | August 18, 2017 | Volume: 42 | Issue: 2 | Pages: 117-121

10.1080/01658107.2017.1355395 | PMID 29563958 Get It

Cam Deformities and Limited Hip Range of Motion Are Associated With Early Osteoarthritic Changes in Adolescent Athletes: A Prospective Matched Cohort Study
Norambuena, Germán A., Howe, Benjamin M., Levy, Bruce A. , Trousdale, Robert T. , Wyles, Cody C. , Larson, Dirk R. , Yuan, Brandon J. , Howe, Benjamin M. , Sierra, Rafael J.

Mayo Clinic

The American Journal of Sports Medicine | August 18, 2017 | Volume: 45 | Issue: 13 | Pages: 3036-3043

10.1177/0363546517719460 | PMID 28820271 Get It

Background: The natural history of femoroacetabular impingement (FAI) remains incompletely understood. In particular, there is limited documentation of joint damage in adolescent patients with limited range of motion (LROM) of the hip, which is commonly associated with FAI. Purpose: To evaluate changes in magnetic resonance imaging (MRI), radiographs, and clinical examinations over 5 years in a group of athletes from a wide variety of sports with asymptomatic LROM of the hip compared with matched controls. Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: The authors screened 226 male and female athletes aged 12 to 18 years presenting for preparticipation sports physical examinations. Using a goniometer, we identified 13 participants with at least one hip having internal rotation <10° with the hip flexed to 90°. Overall, 21 of 26 hips (81%) had internal rotation <10°. These participants were age- and sex-matched to 13 controls with internal rotation >10°. At the time of enrollment, all participants were asymptomatic and underwent a complete hip examination and radiographic imaging with radiographs (anteroposterior [AP] and von Rosen views) and non-arthrogram MRI. Participants returned at 5-year follow-up and underwent repeat hip examinations, imaging (AP and lateral radiographs and non-arthrogram MRI), and hip function questionnaires. MRI scans were classified as “normal” versus “abnormal” based on the presence of any of 13 scored chondral, labral, or osseous abnormalities. Comparisons between the LROM group and control group were performed using generalized linear models (either linear, logistic, or log-binomial regression as appropriate for the outcome) with generalized estimating equations to account for the within-participant correlation due to patients having both hips included. Relative risk (RR) estimates are reported with 95% CIs. Results: At the time of study enrollment, 16 of 26 hips (62%) in the LROM group had abnormal MRI findings within the acetabular labrum or cartilage compared with 8 of 26 hips (31%) in the control group (RR, 2.0; 95% CI, 0.95-4.2; P = .067). The mean alpha angle measured from radial MRI sequences was 58° in the LROM group versus 44° in the control group ( P < .0001). In the LROM group, 13 of 26 hips (50%) had a positive anterior impingement sign, whereas 0 of 26 hips (0%) had a positive anterior impingement sign in the control group. At 5-year follow-up, 18 of 19 hips (95%) in the LROM group had abnormal MRI findings compared with 14 of 26 hips (54%) in the control group (RR, 1.7; 95% CI, 1.1-2.7; P = .014). New or progressive findings were documented on MRI in 15 of 20 hips in the LROM group compared with 8 of 26 hips in the control group (RR, 2.4; 95% CI, 1.2-4.8; P = .011). Six of 22 hips (27%) in the LROM group progressed from Tönnis grade 0 to Tönnis grade 1 in degenerative changes, whereas all 26 hips in the control group remained at Tönnis grade 0 on hip radiographs. In the LROM group, 11 of 22 hips (50%) had a positive anterior impingement sign, whereas 1 of 26 hips (4%) had a positive anterior impingement sign in the control group. A cam deformity (alpha angle >55° on lateral radiographs) was present in 20 of 22 hips (91%) in the LROM group and 12 of 26 hips (46%) in the control group ( P = .0165). The following variables at baseline were associated with an increased risk of degenerative changes at 5-year follow-up for the entire cohort: decreased hip internal rotation, positive anterior impingement sign, decreased hip flexion, increased alpha angle, and presence of a cam lesion. Conclusion: At 5 years, young athletes with LROM of the hip showed increased progressive degenerative changes on MRI and radiographs compared with matched controls. Although the majority of these participants remained asymptomatic, those with features of FAI had radiographic findings consistent with early osteoarthritis. These outcomes suggest that more aggressive screening and counseling of young active patients may be helpful to prevent hip osteoarthritis in those with FAI.
Whole genome sequencing identifies etiology of recurrent male intrauterine fetal death
Shehab, Omar , Tester, David J. , Ackerman, Nicholas C., Cowchock, F. Susan, Ackerman, Michael J.

Mayo Clinic

Prenatal Diagnosis | August 18, 2017 | Volume: 37 | Issue: 10 | Pages: 1040-1045

10.1002/pd.5142 | PMID 28833278 Get It

AbstractObjectiveTo identify the underlying genetic cause for recurrent intrauterine fetal death (IUFD) of males.MethodsWhole genome sequencing was performed on DNA from five healthy obligatory carrier females and an unaffected male offspring of a multigenerational pedigree with recurrent second‐trimester IUFD of males (n = 19). When documented, all deaths occurred at ≤20 weeks of gestation. Hydrops fetalis was diagnosed at death in the most recent case.ResultsFollowing variant filtering based on a recessive X‐linked inheritance pattern, a rare FOXP3 frameshift mutation (p.D303fs*87) that results in a premature truncation of the protein was discovered. Sanger sequencing confirmed the mutation in the affected fetus. The FOXP3 gene encodes for a transcriptional regulator critical to the function of regulatory T cells. FOXP3 mutations are associated with immune dysregulation, polyendocrinopathy, enteropathy, and X‐linked (IPEX) syndrome which exclusively affects males and may present with a potentially life‐threatening complex autoimmune disorder in early childhood.ConclusionsHere, we demonstrate the utility of whole genome sequencing‐based pedigree analysis to identify the genetic cause for recurrent IUFD when chromosome studies, including microarray analysis, are normal. Further studies are needed to determine the prevalence of FOXP3‐mediated IUFD in males. © 2017 John Wiley & Sons, Ltd.
Optical transfer diagnosis differentiating benign and malignant pigmented lesions in a simulated primary care practice
Swanson, David C. , Venneuguès, Rowena Vicencio, Vicencio, S.Q., Garioch, J., Biryulina, M., Ryzhikov, G., Hamre, Børge , Zhao, Lu , Castellana, Frank S., Stamnes, Jakob J., Stamnes, Knut H.

Mayo Clinic

British Journal of Dermatology | August 18, 2017 | Volume: 178 | Issue: 2 | Pages: 541-546

10.1111/bjd.15898 | PMID 28832952 Get It

Comparative analysis of inosine-substituted duplex DNA by circular dichroism and X-ray crystallography
Peters, Justin P. , Kowal, Ewa, Pallan, Pradeep S., Egli, Martin , Maher, L. James , III, Louis James Maher

Mayo Clinic

Journal of Biomolecular Structure and Dynamics | August 18, 2017 | Volume: 36 | Issue: 11 | Pages: 2753-2772

10.1080/07391102.2017.1369164 | PMID 28818035 Get It

GBA mutations in Parkinson disease: earlier death but similar neuropathological features
Adler, Charles H. , Beach, Thomas G. , Shill, H. A., Caviness, John N., Driver‐Dunckley, Erika, Patel, Amit , Sue, Lucia I., Jacobson, Sandra A. , Davis, Kathryn, Belden, Christine M. , Dugger, Brittany N. , Paciga, Sara A. , Winslow, Ashley R. , Hentz, Joseph G. , Adler, C H , Paciga, S A , Shill, Holly A. , Driver‐Dunckley, Erika , Sabbagh, Marwan Noel , Patel, A., Serrano, Geidy E. , Hirst, Warren D. , Dugger, Brittany N

Mayo Clinic

European Journal of Neurology | August 18, 2017 | Volume: 24 | Issue: 11 | Pages: 1363-1368

10.1111/ene.13395 | PMID 28834018 Get It

Background and purpose Mutations in the glucocerebrosidase ( GBA ) gene are known to be a risk factor for Parkinson's disease ( PD ). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene. Methods Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared. Results Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi‐quantitative scores for Lewy‐type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores. Conclusions In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Souza, Jonas A. de, Geyer, Susan M. , Wirth, Lori J. , Menefee, Michael E., Liu, Stephen V. , Shah, Komal , Wright, John, Shah, Manisha H. , Cabanillas, Maria E. , de Souza, Jonas A, Wright, John, Liu, Stephen V

Mayo Clinic

Journal of Clinical Oncology | August 17, 2017 | Volume: 35 | Issue: 29 | Pages: 3315-3321

10.1200/jco.2017.73.0226 | PMID 28817373 Get It

Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) and approved for radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). However, there are no approved second- or third-line therapies. MET is implicated in resistance to VEGFR inhibitors. Cabozantinib is an oral multikinase inhibitor targeting MET in addition to VEGFR and is approved for medullary thyroid cancer. In a phase I study of cabozantinib, five of eight patients with DTC previously treated with a VEGFR-targeted therapy had an objective response to cabozantinib. Patients and Methods Patients with RAI-refractory disease with Response Evaluation Criteria in Solid Tumor (RECIST) measurable disease and evidence of progression on prior VEGFR-targeted therapy were enrolled in this single-arm phase II study. The cabozantinib starting dose was 60 mg/day orally but could be escalated to 80 mg if the patient did not experience a response. Patients underwent tumor assessment according to RECIST v1.1 every 8 weeks. In this study, if at least five of 25 response-evaluable patients had an objective response, cabozantinib would be considered a promising agent in this patient population. Results Twenty-five patients were enrolled. The median age was 64 years, and 64% of patients were men. Twenty-one patients had received only one prior VEGFR-targeted therapy (sorafenib, pazopanib, or cediranib), and four patients had received two such therapies. The most common treatment-related adverse events were fatigue, weight loss, diarrhea, palmar-plantar erythrodysesthesia, and hypertension. One drug-related death was noted. Of the 25 patients, 10 (40%) had a partial response, 13 (52%) had stable disease, and two (8%) had nonevaluable disease. The median progression-free survival and overall survival were 12.7 months and 34.7 months, respectively. Conclusion Cabozantinib demonstrated clinically significant, durable objective response activity in patients with RAI-refractory DTC who experienced disease progression while taking prior VEGFR-targeted therapy.
Systematic Selection of Key Logistic Regression Variables for Risk Prediction Analyses: A Five-Factor Maximum Model
Hewett, Timothy E. , Hurd, Wendy J., Webster, Kate E.

Mayo Clinic

Clinical Journal of Sport Medicine | August 17, 2017 | Volume: 29 | Issue: 1 | Pages: 78-85

10.1097/jsm.0000000000000486 | PMID 28817414 Get It

General and Critical Review Format: The evolution of clinical practice and medical technology has yielded an increasing number of clinical measures and tests to assess a patient's progression and return to sport readiness after injury. The plethora of available tests may be burdensome to clinicians in the absence of evidence that demonstrates the utility of a given measurement. Objective: Thus, there is a critical need to identify a discrete number of metrics to capture during clinical assessment to effectively and concisely guide patient care. Data Sources: The data sources included Pubmed and PMC Pubmed Central articles on the topic. Therefore, we present a systematic approach to injury risk analyses and how this concept may be used in algorithms for risk analyses for primary anterior cruciate ligament (ACL) injury in healthy athletes and patients after ACL reconstruction. Main Results: In this article, we present the five-factor maximum model, which states that in any predictive model, a maximum of 5 variables will contribute in a meaningful manner to any risk factor analysis. Conclusions: We demonstrate how this model already exists for prevention of primary ACL injury, how this model may guide development of the second ACL injury risk analysis, and how the five-factor maximum model may be applied across the injury spectrum for development of the injury risk analysis.
Assessment of Interday Glucose Variability in Type 2 Diabetes
Dadlani, Vikash, Kudva, Yogish C.

Mayo Clinic

Diabetes Technology & Therapeutics | August 17, 2017 | Volume: 19 | Issue: 8 | Pages: 443-445

10.1089/dia.2017.0255 | PMID 28817341 Get It